Thrombophilias: the importance of clinical screening in thromboembolic disease
Keywords:
venous thrombosis, thrombophilia, screeningAbstract
Venous thrombosis occurs as a consequence of inherited acquired or environmental risk factors. Thrombophilic disorders can
be identified in half of patients with venous thrombosis. Factors
such as young age, absence of a precipitating factor, recurrence
and family history, make the diagnosis of thrombophilic disorders
increasingly probable. In this paper the criteria for thrombophilia
screening and the laboratory tests required are reviewed. Furthermore, the clinical value of thrombophilia screening is discussed
considering the current scientific knowledge.
Downloads
References
Samama MM et al. Hémorragies et thromboses – du diagnostic au traitement. Masson, Paris 2004
Lopez JA et al. Deep venous thrombosis. Hematology. Am Soc Hematol Edu Program 2004:439-456.
Rosendaal FR. Venous thrombosis: the role of genes, environment and behavior. Hematology 2005: 1-12.
Cushman M. Inherited risk factors for venous thrombosis. Hematology 2005: 452-457.
Khan S et al. Hereditary thrombophilia. Thrombosis Journal 2006;4:15.
Bauer KA. The thrombophilias: well-defined risk factors with uncertain therapeutic implications. Ann Intern Med 2001;135:367-373.
Seligsohn U et al. Genetic susceptibility to venous thrombosis. NEJM 2001;344:1222-1231.
Nicolaides AN et al. International Consensus Statement: Thrombophilia and venous thromboembolism. Int Angiol 2005;24(1):1-26.
Gouault-Heilmann et al. Recomendations pour une juxte prescription des examens d’hemostase en pratique médicale courante. STV 2006 ;18 :29-42.
Den Heijer M et al. Homocysteine, MTHFR and risk of venous thrombosis: a meta – analysis of published epidemiological studies. J Thromb Haemost 2005; 3:292-299.
Schulman S et al. New concepts in optimal management of anticoagulant therapy for extended treatment of venous thromboembolism. Thromb Haemost 2006;96:258-256.
Christiansen SC et al. Thrombophilia, clinical factors and recurrent thrombotic events. JAMA 2005;293:2352-361.
Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3):338S-428S.
Baglin T et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors:prospective cohort study. Lancet 2003;362:523-526.
Khoon Ho et al. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med
;166:729-736.
Vossen CY et al. Recurrence rate after a first venous thrombosis in patients with familial thrombophilia. Arterioscl Thromb Vasc Biol 2005;25:1992-1997.
Schulman S et al. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 1998;104:332-338.
Khamashta MA et al. The management of thrombosis in the phospholipid antibody syndrome. NEJM 1995;332:993-997.
Khamashta MA (Ed.). Hughes syndrome – Antiphospholipid syndrome. Springer, Londres, 2006, 2ª edição
Additional Files
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Medicina Interna
Open Access
